In a pivotal efficacy trial, NUPLAZID^® (pimavanserin) 34 mg significantly reduced the number and/or severity of hallucinations and delusions in people with Parkinson’s disease psychosis.

The majority of people who took NUPLAZID experienced less frequent and/or less severe symptoms compared with placebo. And, after 6 weeks, some people were no longer experiencing any symptoms. In addition, taking NUPLAZID did not affect motor symptoms compared to placebo.

Continuing to take NUPLAZID as prescribed may help you see results. NUPLAZID may begin to reduce hallucinations and delusions as soon as 4 weeks, but it may take up to 6 weeks to feel the full effect. Not everyone will respond to NUPLAZID. You should speak with your healthcare provider before you stop taking NUPLAZID.

To test the efficacy of NUPLAZID, an FDA-accepted tool was used in a 6-week pivotal efficacy trial in patients with Parkinson's disease psychosis severe enough to require treatment. The tool measures changes in the frequency and/or severity of hallucinations and delusions in people with Parkinson's. In this placebo-controlled trial, NUPLAZID significantly reduced the frequency and/or severity of hallucinations and delusions versus placebo. The trial included 199 adults at least 40 years of age with an average age of 72 years.